etanercept for the treatment of lupus nephritis

Conditions: Lupus Nephritis

Summary: systemic lupus erythematosus (sle) is a chronic, multisystem, autoimmune disease in which the body's immune system attacks its own normal tissues. this abnormal autoimmune response can result in damage to many parts of the body, including the skin, joints, lungs, heart, brain, intestines, and kidneys. kidney problems occur in 60-75 % of lupus patients. the development of lupus-related kidney disease (called lupus nephritis) is associated with an overall worse prognosis. sle is usually treated with drugs that try to block inflammation caused by the immune system. these treatments can create their own problems and they do not cure lupus. the drugs that are often used to treat lupus nephritis include prednisone (steroids), cyclophosphamide (cytoxan), azathioprine (aza or imuran), and mycophenolate mofetil (mmf or cellcept). the main purpose of this study is to evaluate the safety and tolerability of etanercept compared to placebo in combination with standard of care to treat individuals with active lupus nephritis.

kidney problems associated with lupus nephritis range from asymptomatic protein in the urine to rapidly progressive glomerulonephritis, leading to end-stage renal disease. the goal of therapies is to control kidney manifestations in order to avoid kidney failure, the occurrence of other medical problems and death. the treatment of lupus nephritis remains problematic. despite the use of currently available therapies, patients experience disease relapse. over time, patients develop significant morbidity from the disease as well as from medications used for treatment. etanercept, a tnf inhibitor, is proposed as a potential treatment for lupus nephritis. tnf increases the number of reactive b and t cells. tnf levels can be elevated in lupus. etanercept is believed to work by blocking inflammation, and it is hoped that it will lessen the signs and symptoms of lupus-related kidney disease. the purpose of this study is to evaluate the safety and tolerability of etanercept compared to placebo in combination with standard therapy to treat individuals with mild or moderately active lupus nephritis. this study will last 1 year. participants will be randomly assigned to receive either etanercept or placebo in addition to their regular medications. participants will self-administer 50 mg etanercept or placebo injections once a week. they will continue receiving their usual treatment with corticosteroids and either mmf, mycophenolic acid, or aza. treatment with study medication will occur for 24 weeks. there will be a screening visit followed by a randomization visit, where subjects will receive and learn how to administer the study drug. subjects will come to the clinic for 9 study visits. a physical exam and blood and urine collection will occur at most study visits. participants will also be asked to complete a questionnaire on their health at most study visits. subjects will be contacted by phone 5 times during the 24-week period to assess for adverse events and worsening disease status.

Eligibility criteria:
inclusion criteria: * meets at least 4 of the 11 american college of rheumatology (acr) 1982 revised criteria for the classification of sle * active lupus nephritis * currently has antibodies to double-stranded dna (dsdna) * currently receiving treatment consisting of at least 1.5 g/day of mmf or at least 720 mg/day orally of mycophenolic acid or at least 1.5 mg/kg once per day of aza for lupus nephritis, for at least 28 days prior to study entry * stable medication regimen for at least 4 weeks prior to study entry * able and willing to self-administer study drug or has a designated caregiver at home to administer study drug injections * willing to use acceptable forms of contraception for the duration of the study exclusion criteria: * moderately severe anemia * neutropenia * thrombocytopenia * blood creatinine levels greater than 3.0 mg/dl * positive ppd without ongoing treatment for at least 30 days prior to study entry * pulmonary fibrotic changes * active infections (e.g., hiv, hepatitis b virus \[hbv\], hepatitis c virus \[hcv\]) and/or serologic evidence of prior exposure to hepatitis b * received a live vaccine within 3 months prior to study entry * doubled serum creatinine levels within the 3 months prior to study entry or end-stage kidney disease * dialysis-dependent end-stage kidney disease or membranous nephritis * history of cancer. individuals with a history of cervical carcinoma in situ and resected basal and squamous cell carcinomas of the skin are not excluded. * receiving prednisone greater than 20 mg/day or equivalent corticosteroid treatment * pulse intravenous methylprednisolone within 30 days prior to study entry * receiving immunosuppressive agents other than prednisone, mmf, mycophenolic acid, aza, or hydroxychloroquine * oral or intravenous cyclosporine, leflunomide ivig, or plasmapheresis within 3 months prior to study entry * current or previous cyclophosphamide treatment * use of other experimental agent within 90 days prior to study entry * severe, progressive, or uncontrolled kidney, liver, blood, stomach, lung, heart, or brain disease. individuals with any of these conditions that are related to active sle are not excluded. * previous use of rituximab within 12 months prior to study entry * previous or current exposure to any of the following: etanercept (enbrel), adalimumab (humira), infliximab (remicade), or anakinra (kineret) * meets new york heart association classification of congestive heart failure (chf) class iii or greater * history of myocardial infarction or ischemia * current or history of substance abuse * known hypersensitivity to any component of the study drug * poorly controlled or advanced diabetes mellitus * history of multiple sclerosis, transverse myelitis, optic neuritis, or epilepsy * history of noncompliance with other therapies * pregnancy or breastfeeding